The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...

Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course.